- Home
- SCNX vs NNVC Comparison
SCNX vs NNVC Comparison
Compare SCNX & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCNX | NNVC |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | United States | United States |
| Employees | 19 | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0M | 21.2M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | SCNX | NNVC |
|---|---|---|
| Price | $0.42 | $1.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | 331.2K | ★ 340.2K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,097.38 | N/A |
| Revenue Next Year | $239.80 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.85 |
| 52 Week High | $2.60 | $2.23 |
Technical Indicators
Market Signals| Indicator | SCNX | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 56.05 | 56.37 |
| Support Level | $0.37 | $1.35 |
| Resistance Level | $0.47 | $1.53 |
| Average True Range (ATR) | 0.03 | 0.15 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 48.71 | 47.97 |
Price Performance
Historical ComparisonAbout SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.